Adding pirtobrutinib to usual treatment for newly diagnosed Richter transformation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Richter transformation, which is a more aggressive form of chronic lymphocytic leukemia or small lymphocytic lymphoma that has turned into a large B-cell lymphoma.
- You must have a measurable area of disease on a PET/CT scan or by lab tests done within 6 weeks of joining the study.
- You may have had treatments for CLL/SLL in the past, but you cannot have taken pirtobrutinib before.
- You should not have had many previous treatments for Richter transformation itself, except for a short course of steroids for symptom control.
- You must be at least 18 years old and be in fairly good physical condition (able to care for yourself, up and about more than half of your waking hours).
- Your heart function must be okay, with no major heart problems, and you must be able to swallow oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
This Phase 2 study tests zanubrutinib plus tislelizumab, with or without sonrotoclax, for people whose CLL has changed into Richter transformation (an aggressive lymphoma). It aims to improve anti-cancer response while tracking side effects and safety.
Hear when a new Richter Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.